AIRE是由545个氨基酸组成的一种具有转录活化潜能的DNA结合蛋白,从N末端开始,AIRE由一个可能介导DNA结合的半胱氨酸天冬氨酸蛋白酶募集结构域(caspase recruitment domain, CARD)、一个核定位序列(nuclear localization sequences, NLS)、一个SAND结构域、两个植物同源结构域(plant homeodomain, PHD)锌指、一个脯氨酸富集...
AIRE是由545个氨基酸组成的一种具有转录活化潜能的DNA结合蛋白,从N末端开始,AIRE由一个可能介导DNA结合的半胱氨酸天冬氨酸蛋白酶募集结构域(caspase recruitment domain, CARD)、一个核定位序列(nuclear localization sequences, NLS)、一个SAND结构域、两个植物同源结构域(plant homeodomain, PHD)锌指、一个脯氨酸富集...
Gene Shinozaki 🇺🇸 vs B-Art 🇳🇱 | GBB21 Beatbox世界联赛 | 个人组16进8 2330 1 18:44 App Dlow 看Abo IceGBB23 海选 现场和在家双视角 Reaction 2064 4 17:52 App Dlow 看NaPoM GBB23 海选 现场和在家双视角 Reaction 18.2万 853 9:57 App RIVER' 🇫🇷 vs Hiss 🇰🇷 | ...
抗PD-1抗体和其用途.pdf,本公开涉及所分离单克隆抗体或其抗原结合片段,所述所分离单克隆抗体或其抗原结合片段与PD‑1特异性结合并且阻断PD‑1与PD‑L1/PD‑L2之间的相互作用。本公开还涉及作为嵌合抗体、人源化抗体、双特异性抗体、衍生化抗体、单链抗体、融合蛋白
在一些实施方案中, TM TM TM TM 用NOVOGENE NOVOPM Cancer Panel测定法来确定TMB。NOVOGENE NOVOPM Cancer Panel测 43 43 CN 110678483 A 说明书 42/58页 定法是全面NGS癌症系列,其分析548个基因的完整编码区和21个基因的内含子(代表约 1.5Mb的DNA),根据National Comprehensive Cancer Network(...
[72]. Moreover, interferon-stimulated gene 15 (ISG15) can inhibit N-glycosylation of PD-L1 by promoting PD-L1 ubiquitination and degradation [73]. GFAT1, which produces a precursor for N-glycosylation, was shown to be required for PD-L1 expression and stability. Inhibiting GFAT1 suppresses ...
A subsequent genome-wide in vivo screen using T cell-specific transposon mutagenesis identified PDCD1, which encodes the inhibitory receptor programmed death-1 (PD-1), as a master gene that suppresses oncogenic T cell signalling. Mono- and bi-allelic deletions of PDCD1 are also recurrently ...
英文名称:Lymphocyte activation gene 3 protein上市药物数量:0中文名称:淋巴细胞活化基因3蛋白临床药物数量:18靶点别称:LAG-3,CD223,FDC,LAG3,Protein FDC最高研发阶段:临床LAG3 在肿瘤上的分布临床数据显示,在多种癌症类型中,如黑色素瘤、结肠癌、乳腺癌等,肿瘤浸润淋巴细胞(TILs)表达LAG-3,这与癌细胞侵略性的...
(axicabtageneciloleucel)、阿昔替尼(axitinib)、阿扎胞苷(azacitidine)、azedra(碘苄胍i131(iobenguanei131))、bavencio(阿维单抗)、贝利司他(beleodaq)(贝利司他(belinostat))、贝利司他、盐酸苯达莫司汀(bendamustinehydrochloride)、bendeka(盐酸苯达莫司汀(bendamustinehydrochloride))、besponsa(奥英妥珠单抗(...
To investigate the safety and efficacy of cardunnilizumab in the treatment of advanced mucosal, acral and cutaneous malignant melanoma and advanced renal cell carcinoma. Primary end point: objective response rate (ORR) Secondary end point: progression-free survival (PFS), disease control rate (DCR...